Extension of Reexportation Period.

Issuing agencies

Abstract

This proposed rule would amend the regulations of the Drug Enforcement Administration (DEA) to extend the time allowed for reexports of controlled substances outside of the European Economic Area from 180 days from the date of original release from U.S. Customs and Border Protection to 365 days from that original release date.

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 189 (Thursday, October 1, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 189 (Thursday, October 1, 2026)]
[Proposed Rules]
[Pages 62357-62361]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-20084]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1312

[Docket No. DEA-730]
RIN 1117-AB87


Extension of Reexportation Period.

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Notice of Proposed Rulemaking.

-----------------------------------------------------------------------

SUMMARY: This proposed rule would amend the regulations of the Drug 
Enforcement Administration (DEA) to extend the time allowed for 
reexports of controlled substances outside of the European Economic 
Area from 180 days from the date of original release from U.S. Customs 
and Border Protection to 365 days from that original release date.

DATES: Electronic comments must be submitted, and written comments must 
be postmarked, on or before November 30, 2026. Commenters should be 
aware that the electronic Federal Docket Management System will not 
accept any comments after 11:59 p.m. Eastern Time on the last day of 
the comment period.
    All comments concerning collections of information under the 
Paperwork Reduction Act must be submitted to the Office of Management 
and Budget on or before November 30, 2026.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-730'' on all correspondence, including any 
attachments.
    <bullet> Electronic comments: DEA encourages that all comments be 
submitted electronically through the Federal eRulemaking Portal which 
provides the ability to type short comments directly into the comment 
field on the web page or attach a file for lengthier comments. Please 
go to <a href="http://www.regulations.gov">http://www.regulations.gov</a> and follow the online instructions at 
that site for submitting comments. Upon completion of your submission, 
you will receive a Comment Tracking Number for your comment. Please be 
aware that submitted comments are not instantaneously available for 
public view on <a href="http://Regulations.gov">Regulations.gov</a>. If you have received a Comment Tracking 
Number, your comment has been successfully submitted and there is no 
need to resubmit the same comment.
    <bullet> Paper comments: Paper comments that duplicate electronic 
submissions are not necessary. Should you wish to mail a paper comment 
in lieu of an electronic comment it should be sent via regular or 
express mail to: Drug Enforcement Administration, Attn: DEA Federal 
Register Representative/DPW, 8701 Morrissette Drive, Springfield, VA 
22152.
    <bullet> Paperwork Reduction Act comments: All comments concerning 
collections of information under the Paperwork Reduction Act must be 
submitted to the Office of Information and Regulatory Affairs, OMB, 
Attn: Desk Officer for DOJ, Washington, DC 20503. Please state that 
your comment refers to RIN 1117-AB87/Docket No. DEA-730.

FOR FURTHER INFORMATION CONTACT: Heather E. Achbach, Regulatory 
Drafting and Policy Support Section, Diversion Control Division, Drug 
Enforcement Administration; Mailing Address: 8701 Morrissette Drive, 
Springfield, VA 22152; Telephone: (571) 362-3261.

SUPPLEMENTARY INFORMATION:

I. Posting of Public Comments

    Please note that all comments received are considered part of the 
public record. They will, unless reasonable cause is given, be made 
available by DEA for public inspection online at <a href="http://www.regulations.gov">http://www.regulations.gov</a>. Such information includes personal identifying 
information (such as your name, address, etc.) voluntarily submitted by 
the commenter. The Freedom of Information Act applies to all comments 
received. If you want to submit personal identifying information (such 
as your name, address, etc.) as part of your comment, but do not want 
it to be made publicly available, you must include the phrase 
``PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your 
comment. You must also place all of the personal identifying 
information you do not want made publicly available in the first 
paragraph of your comment and identify what information you want 
redacted.
    If you want to submit confidential business information as part of 
your comment, but do not want it to be made publicly available, you 
must include the phrase ``CONFIDENTIAL BUSINESS INFORMATION'' in the 
first paragraph of your comment. You must also prominently identify the 
confidential business information to be redacted within the comment.
    Comments containing personal identifying information or 
confidential business information identified as directed above will be 
made publicly available in redacted form. If a comment has so much 
confidential business information that it cannot be effectively 
redacted, all or part of that comment may not be made publicly 
available. Comments posted to <a href="http://www.regulations.gov">http://www.regulations.gov</a> may include 
any personal identifying information (such as name, address, and phone 
number) included in the text of your electronic submission that is not 
identified as confidential as directed above.
    An electronic copy of this proposed rule and a plain language 
summary are available at <a href="http://www.regulations.gov">http://www.regulations.gov</a> for easy reference.

II. Legal Authority

    The Controlled Substances Act (CSA) grants the Attorney General 
authority to promulgate rules and regulations relating to the 
registration and control of the manufacture, distribution, and 
dispensing of controlled substances and listed chemicals and the 
efficient execution of his statutory functions under the CSA.\1\ The 
Attorney General is further authorized by the CSA to promulgate rules 
and regulations relating to the registration and control of importers 
and exporters of controlled substances and listed chemicals.\2\ The

[[Page 62358]]

Attorney General has delegated this authority to the Administrator of 
DEA.\3\
---------------------------------------------------------------------------

    \1\ 21 U.S.C. 821, 822(a), 871(b), and 957(b).
    \2\ 21 U.S.C. 958(f).
    \3\ 28 CFR 0.100(b).
---------------------------------------------------------------------------

III. Background and Purpose of the Proposed Rule

    The Controlled Substances Export Reform Act of 2005, Public Law 
109-57, 119 Stat. 592 (CSERA) amended the CSA to allow ``any controlled 
substance that is in schedule I or II, or is a narcotic drug in 
schedule III or IV, to be exported from the United States to a country 
for subsequent export from that country to another country'' if 
specific conditions are met.\4\ Prior to enactment of the CSERA, it was 
impermissible to export a controlled substance in schedules I and II or 
a narcotic controlled substance in schedules III and IV for the purpose 
of reexport to another country. Such controlled substances could 
lawfully be exported only to the immediate country where they would be 
consumed. DEA issued a final rule implementing the CSERA in 2007.\5\ 
Although the Notice of Proposed Rulemaking (NPRM) corresponding to that 
final rule proposed a 90-day time period for reexports,\6\ the final 
rule extended this time period to 180 days in response to the public 
comments received.\7\
---------------------------------------------------------------------------

    \4\ 21 U.S.C. 953(f).
    \5\ 72 FR 72921 (Dec. 26, 2007).
    \6\ 71 FR 61436, 61437 (Oct. 18, 2006).
    \7\ 72 FR at 72923.
---------------------------------------------------------------------------

    The Improving Regulatory Transparency for New Medical Therapies Act 
was enacted in 2015 as Public Law 114-89, 129 Stat. 698 (IRTNMTA). In 
relevant part, the IRTNMTA allows reexports from one European Economic 
Area (EEA) member to another \8\ if certain conditions are met by each 
country to which the controlled substance is subsequently exported. The 
IRTNMTA requires, within 30 days of the reexportation, that the person 
who exported the controlled substance from the United States deliver to 
the Attorney General documentation certifying the reexport and 
information concerning the consignee, country, and product.\9\ 
Furthermore, the Attorney General cannot promulgate or enforce any 
regulation, subregulatory guidance, or enforcement policy that impedes 
reexportation of any controlled substance among EEA countries, 
including any requirement that reexportation from the first country to 
the second or from the second to another country occur within a 
specified period of time.\10\ DEA issued a final rule implementing the 
IRTNMTA in 2016.\11\
---------------------------------------------------------------------------

    \8\ 21 U.S.C. 953(f)(5).
    \9\ 21 U.S.C. 953(f)(6).
    \10\ 21 U.S.C. 953(g).
    \11\ 81 FR 96992 (Dec. 30, 2016).
---------------------------------------------------------------------------

    Except for reexports among countries of the EEA in accordance with 
21 U.S.C. 953(f), DEA's current regulation on reexportation, codified 
at 21 CFR 1312.22(h)(6), allows any controlled substance listed in 
schedule I or II or any narcotic drug listed in schedule III or IV to 
be reexported only within 180 days of the date when the controlled 
substance was released by U.S. Customs and Border Protection (CBP). The 
purpose of this proposed rule is to extend the time period during which 
such controlled substances may be reexported once released by CBP 
(except for reexports among countries of the EEA in accordance with 21 
U.S.C. 953(f)). DEA has found that the current limit of 180 days is 
often too short to allow reexportation because of circumstances beyond 
the control of the initial exporter. When these circumstances occur, 
they create additional difficulties for the exporter and DEA. These 
additional difficulties include delays in facilities receiving their 
licenses, which can cause receipt of shipments to be postponed; issues 
fulfilling back orders, and supply chain issues. This proposed rule 
would amend DEA regulations to extend the reexportation period from up 
to 180 days to a limit of 365 days after the release by a customs 
officer of the United States. This change will ease the difficulties 
facing exporters and DEA when uncontrollable circumstances delay 
reexportation.

IV. Need for Regulatory Changes

    Regulatory changes to existing DEA regulations are needed to extend 
the time period necessary for the reexportation of certain controlled 
substances once released by a customs officer of the United States. DEA 
has found that the current limit of 180 days is being exceeded because 
of circumstances beyond the control of the initial exporter. DEA has 
found that 180 days has not been a sufficient amount of time for 
companies to perform logistical operations needed for reexportation, 
such as storing and moving exports. Compliance with the 180-day limit 
can be infeasible because of manufacturing issues; geopolitical issues, 
like closures of airspace; facility licensing delays; and the inability 
to fulfill back orders. Therefore, this proposed rule would amend 
existing DEA regulations in 21 CFR 1312.22(h)(6) in order to increase 
the limit from a maximum of 180 days to a maximum of 365 days for 
reexportation of certain controlled substances.

V. Regulatory Analyses

Executive Orders 12866, 13563, and 14192 (Regulatory Review)

    The Office of Information and Regulatory Affairs in the Office of 
Management and Budget (OMB) has determined that this rulemaking is a 
``significant regulatory action'' under section 3(f) of Executive Order 
(E.O.) 12866, Regulatory Planning and Review, 58 FR 51735, 51738 (Sep. 
30, 1993), but it is not an economically significant action under 
section 3(f)(1). Accordingly, DEA has submitted this proposed rule to 
OMB for review. This proposed rule has been drafted and reviewed in 
accordance with section 1(B) of E.O. 12866, as well as section 1(b) of 
E.O. 13563, Improving Regulation and Regulatory Review, 76 FR 3821, 
3821 (Jan. 18, 2011), and E.O. 14192 Unleashing Prosperity Through 
Deregulation, 90 FR 9065 (Jan. 31, 2025).
    This proposed rule is expected to be a deregulatory action under 
E.O. 14192 because it has a total cost less than zero. DEA estimates a 
total cost savings of $349 annually as a result of the proposed rule, 
which equates to a present value of $2,451 at a seven percent discount 
rate over a 10-year analysis period.

Assessment of Benefits and Costs

    Currently, except in the case of reexports among countries in the 
EEA, the deadline for reexports is 180 days from the date of original 
release from CBP. If the exporter anticipates that the reexport 
deadline will be exceeded, it must notify DEA of the anticipated delay 
and request a one-time waiver of this requirement. This proposed rule 
would amend DEA regulations to extend the time allowed for 
reexportation from 180 days to 365 days. By extending the deadline to 
365 days, DEA estimates these notifications and requests for waivers 
from exporters will be virtually eliminated, generating cost savings 
for exporters and DEA. DEA has examined the benefits and costs of this 
proposed rule as described below.
    As stated above, currently the deadline is 180 days for reexport 
for non-EEA countries. The U.S. exporter must notify DEA and request a 
one-time waiver if there will be a delay. There is no standard method 
for reporting the delay. Typically, the registrant calls or emails 
DEA's Import/Export Section, the registration call center, or a field 
office to notify DEA about the probable delay and to request guidance. 
The exporter is

[[Page 62359]]

referred to DEA's Office of Diversion Control Policy, Policy Section 
for guidance, and the Policy Section generally suggests that the 
exporter needs to submit a request for a waiver of the anticipated 
violation of the 180-day deadline.
    DEA estimates that, on average, there are currently three delays 
per year, where the exporter notifies DEA of the anticipated delay and 
the exporter submits a request for a waiver. By extending the deadline 
to 365 days, DEA estimates these notifications and requests for waivers 
from exporters will be virtually eliminated, generating cost savings 
for exporters. The primary cost savings from this proposed rule would 
result from registrants not needing to notify DEA of the delay and 
submit a request for a waiver. Based on an estimated two hours for the 
exporter to contact DEA and to submit a request for a waiver, DEA 
estimates a cost savings of $116.20 per each event (notification and 
request for waiver) or annual cost savings associated with this rule 
for exporters of $348.60.\12\
---------------------------------------------------------------------------

    \12\ These figures are based on the U.S. Bureau of Labor 
Statistics (BLS) estimates for occupation code 13-1041: Compliance 
Officer. The mean hourly wage for that position according to the May 
2024 National Occupational Employment and Wage Estimates United 
States, <a href="https://www.bls.gov/oes/current/oes_nat.htm">https://www.bls.gov/oes/current/oes_nat.htm</a>, is $40.86. 
Based on the BLS report, ``Employer Costs for Employee 
Compensation--March 2025,'' <a href="https://www.bls.gov/news.release/pdf/ecec.pdf">https://www.bls.gov/news.release/pdf/ecec.pdf</a>, for private industry workers, total benefits is 29.7 
percent and `wages and salaries' is 70.3 percent of total 
compensation. The 30 percent of total compensation equates to 42.2 
percent of wages and salaries (29.7/70.3 = 0.422). Therefore, an 
additional 42.2 percent load is added to the wage rate to account 
for benefits. Factoring in benefits, then, the cost of one hour's 
work for a compliance officer is $40.86 multiplied by 1.422, or 
$58.10. The estimated two hours for a compliance officer to write 
and submit exception requests therefore equates to $116.20 (2 x 
$58.10) per delay. Multiplying $116.20 by the three delays that 
occur annually equates to a total annual cost saving of $348.60.
---------------------------------------------------------------------------

    There are also some benefits that cannot be quantified. By 
extending the deadline from 180 to 365 days, exporters will gain more 
flexibility in adjusting to any unforeseen logistical circumstances and 
conducting reexports. Currently, exporters may make decisions that are 
not economically optimal in order to meet the 180-day deadline. By 
essentially doubling the deadline to 365 days, the proposed rule would 
allow exporters to explore economically optimal options and minimize 
the costs associated with meeting the 180-day deadline.
    DEA may also save costs from not having to respond to inquiries and 
not processing waiver requests. However, there are only approximately 
three such inquiries per year, so any cost savings to DEA would be 
minimal.
    In summary, this proposed rule would essentially eliminate the need 
for an exporter to contact DEA and request a waiver of the requirement 
to reexport before the deadline. DEA estimates a cost savings of 
$116.20 per request not made, resulting in annual cost savings of 
$348.60 ($349 rounded) for an estimated three delays per year. An 
annual cost savings of $349 over a 10-year time horizon equates to a 
present value of cost savings of $2,451 at seven percent discount rate.

Executive Order 12988 (Civil Justice Reform)

    This proposed rule meets the applicable standards set forth in 
sections 3(a) and 3(b)(2) of E.O. 12988, 61 FR 4729 (Feb. 5, 1996), to 
eliminate ambiguity, minimize litigation, establish clear legal 
standards, and reduce burdens.

Executive Order 13132 (Federalism)

    This proposed rule does not have federalism implications warranting 
the application of E.O. 13132, 64 FR 43255 (Aug. 4, 1999). The proposed 
rule does not have substantial direct effects on the States, on the 
relationship between the national government and the States, or on the 
distribution of power and responsibilities among the various levels of 
government.

Executive Order 13175 (Consultation and Coordination With Indian Tribal 
Governments)

    This proposed rule does not have tribal implications warranting the 
application of E.O. 13175, 65 FR 67249 (Nov. 6, 2000). The proposed 
rule does not have substantial direct effects on one or more Indian 
tribes, on the relationship between the Federal government and Indian 
tribes, or on the distribution of power and responsibilities between 
the Federal government and Indian tribes.

Executive Order 14267 (Reducing Anti-Competitive Regulatory Barriers)

    The proposed rule does not reduce competition, entrepreneurship, 
and innovation and therefore does not run afoul of E.O. 14267, 90 FR 
15629 (Apr. 15, 2025).

Executive Order 14294 (Overcriminalization of Federal Regulations)

    E.O. 14294, 90 FR 20363 (May 14, 2025), specifies that all NPRMs 
and final rules published in the Federal Register, the violation of 
which may constitute criminal regulatory offenses, should include a 
statement identifying that the rule or proposed rule is a criminal 
regulatory offense, the authorizing statute, and the mens rea 
requirement for each element of the offense. This final rule does not 
involve a criminal regulatory offense and thus E.O. 14294 does not 
apply.

Regulatory Flexibility Act

    The Regulatory Flexibility Act (RFA) requires an agency to prepare 
a Regulatory Impact Analysis to evaluate options for regulatory relief 
of small entities unless it can certify that the proposed rule will not 
have a significant impact on a substantial number of small entities. 
DEA has analyzed the economic impact of each provision of this proposed 
rule and estimates that it will have minimal economic impact on 
affected entities, including small businesses, nonprofit organizations, 
and small governmental jurisdictions.
    This proposed rule would amend DEA regulations to extend the time 
allowed for reexportation of controlled substances from 180 days to 365 
days. As discussed above, by extending the deadline to 365 days, this 
proposed rule would essentially eliminate the need for an exporter to 
contact DEA and request a waiver of the requirement to reexport before 
the deadline. DEA estimates cost savings of $116.20 per request or an 
annual cost savings of $348.60 for the estimated three delays that 
occur each year.
    Based on the number of inquiries received per year, DEA estimates 
there are three controlled substances exporters affected by this 
proposed rule. DEA assumes the three registrations represent three 
different entities, meaning that, at most, three small entities are 
affected by this proposed rule. The North American Industry 
Classification System (NAICS) code 424210 (Drugs and Druggists' 
Sundries Merchant Wholesalers) best represents the industry affected by 
this proposed rule. Based on data from the U.S. Small Business 
Administration \13\ and the U.S. Census Bureau's Statistics of U.S. 
Businesses (SUSB), 6,703 of the total 7,012 firms in NAICS industry 
code 424210 are small businesses with fewer than 250 employees.\14\ The 
three small entities affected by this proposed rule thus account for 
0.04 percent of the relevant small businesses, and they accordingly do 
not amount to a

[[Page 62360]]

``substantial'' number of the small entities in NAICS code 424210. 
Therefore, DEA certifies that this proposed rule will not, if 
promulgated, have a significant economic impact on a substantial number 
of small entities.
---------------------------------------------------------------------------

    \13\ Table of size standards, U.S. Small Business 
Administration, <a href="https://www.sba.gov/document/support-table-size-standards">https://www.sba.gov/document/support-table-size-standards</a> (last accessed Sept. 30, 2025).
    \14\ 2022 SUSB Annual Datasets by Establishment Industry, ``U.S. 
& states, NAICS, detailed employment sizes (U.S., 6-digit and 
states, NAICS sectors),'' <a href="https://www.census.gov/data/tables/2022/econ/susb/2022-susb-annual.html">https://www.census.gov/data/tables/2022/econ/susb/2022-susb-annual.html</a> (last accessed Sept. 30, 2025).
---------------------------------------------------------------------------

Unfunded Mandates Reform Act of 1995

    In accordance with the Unfunded Mandates Reform Act of 1995 
(UMRA),\15\ DEA has determined that this action would not result in any 
Federal mandate that may result ``in the expenditure by State, local, 
and tribal governments, in the aggregate, or by the private sector, of 
$100,000,000 or more (adjusted annually for inflation) in any 1 year.'' 
Therefore, neither a Small Government Agency Plan nor any other action 
is required under the UMRA.
---------------------------------------------------------------------------

    \15\ 2 U.S.C. 1501 et seq.
---------------------------------------------------------------------------

Paperwork Reduction Act

    This proposed rule would modify existing collections of information 
requirements under the Paperwork Reduction Act (PRA).\16\ Pursuant to 
the PRA,\17\ DEA has identified the collections of information below 
related to this proposed rule. A person is not required to respond to a 
collection of information unless it displays a valid OMB control 
number.\18\
---------------------------------------------------------------------------

    \16\ 44 U.S.C. 3501 et seq.
    \17\ 44 U.S.C. 3507(d).
    \18\ Copies of existing information collections approved by OMB 
may be obtained at <a href="http://www.reginfo.gov/public/do/PRAMain">http://www.reginfo.gov/public/do/PRAMain</a>.
---------------------------------------------------------------------------

A. Collections of Information Associated With the Proposed Rule
    Title: Application for Permit to Export Controlled Substances-DEA 
161, Application for Permit to Export Controlled Substances for 
Subsequent Reexport-DEA 161R.
    OMB Control Number: 1117-0004.
    Form Number: DEA-161/161R/161R-EEA.
    DEA is proposing to amend its regulations in order to extend the 
time allowed for reexportation of certain controlled substances from 
180 days from the date of original release from CBP to 365 days from 
that original release date. This change will affect the instructions 
for completing form DEA-161R, but it will not require submission of 
additional information to complete that form, nor will it affect form 
DEA-161.
    DEA anticipates no change in the number of respondents or the 
burden associated with this information collection as a result of this 
proposed rule. DEA estimates the following number of respondents and 
burden associated with this collection of information:\19\
---------------------------------------------------------------------------

    \19\ This information collection request pertains to the use of 
DEA Forms 161 and 161R generally, and not just to the proposed 
revision to the time allowed for reexportation. Accordingly, the 
burden estimates provided here are for all uses of Forms 161 and 
161R.
---------------------------------------------------------------------------

    <bullet> Number of respondents: 162.
    <bullet> Number of responses: 10,180.
    <bullet> Frequency of response: 62.83951 (as needed, calculated 
average).
    <bullet> Burden per response: 0.5535363.\20\
---------------------------------------------------------------------------

    \20\ This is the weighted average burden per response for forms 
DEA-161, 161R, and 161R-EEA.
---------------------------------------------------------------------------

    <bullet> Total annual hour burden: 5,635.
B. Request for Comments Regarding the Proposed Collections of 
Information
    Written comments and suggestions from the public and affected 
entities concerning the proposed collections of information are 
encouraged. Under the PRA, DEA is required to provide a notice 
regarding the proposed collections of information in the Federal 
Register with the proposed rule and solicit public comment. Pursuant to 
section 3506(c)(2) of the PRA (44 U.S.C. 3506(c)(2)), DEA solicits 
comments on the following issues:
    <bullet> Whether the proposed collection of information is 
necessary for the proper performance of the functions of DEA, including 
whether the information will have practical utility.
    <bullet> The accuracy of DEA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used.
    <bullet> Recommendations to enhance the quality, utility, and 
clarity of the information to be collected.
    <bullet> Recommendations to minimize the burden of the collection 
of information on those who are to respond, including through the use 
of automated collection techniques or other forms of information 
technology.
    All comments concerning collections of information under the PRA 
must be submitted to the Office of Information and Regulatory Affairs, 
OMB, Attention: Desk Officer for DOJ, Washington, DC 20503. Please 
state that your comments refer to RIN 1117-AB87/Docket No. DEA-730. All 
comments must be submitted to OMB on or before November 30, 2026. The 
final rule will respond to any OMB or public comments on the 
information collection requirements contained in this proposed rule.
    If you need a copy of the proposed information collection 
instrument(s) with instructions or additional information, please 
contact the Regulatory Drafting and Policy Support Section, Diversion 
Control Division, Drug Enforcement Administration; Mailing Address: 
8701 Morrissette Drive, Springfield, VA 22152; Telephone: (571) 362-
3261.

List of Subjects

21 CFR Part 1301

    Administrative practice and procedure, Drug traffic control, 
Security measures.

21 CFR Part 1309

    Administrative practice and procedure, Drug traffic control, 
Exports, Imports, Security measures.

21 CFR Part 1312

    Administrative practice and procedure, Drug traffic control, 
Exports, Imports.

21 CFR Part 1321

    Administrative practice and procedure.

    For the reasons stated in the preamble, DEA proposes to amend 21 
CFR part 1312 as follows:

PART 1312--IMPORTATION AND EXPORTATION OF CONTROLLED SUBSTANCES

0
1. The authority citation for part 1312 continues to read as follows:

    Authority:  21 U.S.C. 821, 871(b), 952, 953, 954, 957, 958.

0
2. In Sec.  1312.22, revise paragraph (h)(6) to read as follows:


Sec.  1312.22  Application for export or reexport permit; return 
information.

* * * * *
    (h) * * *
    (6) Except in the case of reexports among countries of the European 
Economic Area in accordance with section 1003(f) of the Act (21 U.S.C. 
953(f)), the controlled substance will be reexported from the first 
country to the second country (or second countries) no later than 365 
calendar days after the controlled substance was released by a customs 
officer from the United States.
* * * * *

Signing Authority

    This document of the Drug Enforcement Administration was signed on 
September 21, 2026, by DEA Administrator Terrance C. Cole. That 
document with the original signature and date is maintained by DEA. For 
administrative purposes only, and in compliance with requirements of 
the Office of the Federal Register, the undersigned DEA Federal 
Register Liaison Officer has been authorized to sign and submit the 
document in

[[Page 62361]]

electronic format for publication, as an official document of DEA. This 
administrative process in no way alters the legal effect of this 
document upon publication in the Federal Register.

Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2026-20084 Filed 9-30-26; 8:45 am]
BILLING CODE 4410-09-P


</pre></body>
</html>